STAT stories you may have missed 

Private equity firms are increasingly buying medical practices. What does that mean for patients? 

Opinion: Can you sue an algorithm for malpractice? It depends. 

The price of Gilead’s newest HIV medication should be cut in half, the authors of a new study argue. 

The CBD industry is panning a recent report to Congress as “more of the same.”

The stats are in: Gene therapy is booming like never before. 

This biotech company went public during the stock market’s worst week since 2008.